FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800354105> ?p ?o ?g. }

• W2800354105 endingPage "S289" @default.
• W2800354105 startingPage "S289" @default.
• W2800354105 abstract "Purpose: Celecoxib is currently used as an analgesic in knee osteoarthritis (OA) patients with proven efficacy. Besides solely being a drug with analgesic properties, evidence on the OA disease modifying properties of celecoxib is accumulating. On the other hand, other studies do not confirm OA disease modifying properties of celecoxib. However, these studies evaluated effects of orally administered celecoxib, which not surprisingly will result in lower local concentrations of celecoxib in the knee joint. In this study we hypothesized that celecoxib can be used as an OA-modulatory drug when injected intra-articularly in the knee joint. Since intra-articular administration of celecoxib means that the drug will interact with different intra-articular tissues such as the cartilage, synovium, Hoffa's Fat Pad (HFP) and meniscus we first evaluated the ability of celecoxib to modulate prostanoid release from these intra-articular tissues. Furthermore, we investigated whether prostanoid-reducing actions of celecoxib on different intra-articular tissues is accompanied by a modulation of the expression of aggrecanases, which are important proteolytic enzymes involved in OA pathophysiology. Finally, we sought to determine potential chondroprotective effects of a single intra-articular celecoxib bolus injection in the rat ACLT/pMMx model for OA. Methods: Upon medical ethical approval, cartilage, synovium, HFP and meniscus were obtained after total knee replacement from nine patients with knee OA. Explants were generated and cultured at a ratio of 100 mg tissue per mL culture medium for 24 hours in the presence or absence of 10 μM celecoxib. Presence of prostaglandin subtypes PGE2, PGF2α, PGD2 and (thromboxane B2) TXB2 was determined quantitatively by specific ELISAs. Gene expression levels of ADAMTS4 and ADAMTS5 was evaluated in the intra-articular tissues by means of RT-qPCR. For in vivo experiments OA was induced by performing anterior cruciate ligament transection (ACLT) + partial medial menisectomy (pMMx) in the right knees of 14 male Lewis rats (12-weeks old). Four weeks after OA induction, both the OA-induced and contralateral healthy knees were injected with 25 μL of 0.9 % NaCl or 9.7 nM celecoxib (92.25 ng celecoxib). Twelve weeks after injection, rats were sacrificed and OA severity was assesed by two blinded observers using the OARSI histopathology initiative for the rat (n = 7 per experimental group). Results: Average concentration ranges for the different prostanoids were 26216-385039 pg/mL for PGE2, 5496-69,574 pg/mL for PGF2α, 3848-43830 for PGD2 and 388-9102 pg/mL for TXB2. Celecoxib, at a dose of 10 μM, was able to significantly reduce PGE2, PGF2α, PGD2 and TXB2 release in cartilage, synovium, HFP and meniscus. Average fold reduction in prostanoid release for different intra-articular tissues tested ranged from 25- to 62-fold for PGE2, 9-fold to 20-fold for PGF2α, 8-fold to 23-fold for PGD2 and 2- to 5-fold for TXB2. Celecoxib significantly reduced gene expression levels of both ADAMTS4 and ADAMTS5 in cartilage, synovium, HFP and meniscus. OA levels based upon OARSI scoring were significantly reduced in OA-induced knees treated with bolus celecoxib (P = 0.009 by observer 1 and P = 0.032 by observer 2) compared to OA-induced knees injected with 0.9% NaCl (Fig. 1). Conclusions: Different intra-articular tissues secrete various prostanoid subtypes. These prostanoid subtypes are involved in catabolic processes and celecoxib is able to reduce the release of these prostanoids from cartilage, synovium, HFP and meniscus, but is also able to reduce the expression of aggrecanases which are important enzymes involved in cartilage matrix degradation. A single bolus injection with celecoxib protects against OA progression in vivo and therefore this study reinforces the potential of celecoxib as a potential OA disease-modifying drug when used intra-articularly." @default.
• W2800354105 created "2018-05-17" @default.
• W2800354105 creator A5001953166 @default.
• W2800354105 creator A5003187179 @default.
• W2800354105 creator A5003534631 @default.
• W2800354105 creator A5010022270 @default.
• W2800354105 creator A5014369135 @default.
• W2800354105 creator A5023741525 @default.
• W2800354105 creator A5038014178 @default.
• W2800354105 creator A5085736490 @default.
• W2800354105 date "2018-04-01" @default.
• W2800354105 modified "2023-10-14" @default.
• W2800354105 title "Celecoxib modulates release of different prostanoid subtypes by intra-articular tissues: towards celecoxib based intra-articular treatment for OA modulation?" @default.
• W2800354105 doi "https://doi.org/10.1016/j.joca.2018.02.581" @default.
• W2800354105 hasPublicationYear "2018" @default.
• W2800354105 type Work @default.
• W2800354105 sameAs 2800354105 @default.
• W2800354105 citedByCount "0" @default.
• W2800354105 crossrefType "journal-article" @default.
• W2800354105 hasAuthorship W2800354105A5001953166 @default.
• W2800354105 hasAuthorship W2800354105A5003187179 @default.
• W2800354105 hasAuthorship W2800354105A5003534631 @default.
• W2800354105 hasAuthorship W2800354105A5010022270 @default.
• W2800354105 hasAuthorship W2800354105A5014369135 @default.
• W2800354105 hasAuthorship W2800354105A5023741525 @default.
• W2800354105 hasAuthorship W2800354105A5038014178 @default.
• W2800354105 hasAuthorship W2800354105A5085736490 @default.
• W2800354105 hasBestOaLocation W28003541051 @default.
• W2800354105 hasConcept C120665830 @default.
• W2800354105 hasConcept C121332964 @default.
• W2800354105 hasConcept C126322002 @default.
• W2800354105 hasConcept C142724271 @default.
• W2800354105 hasConcept C181199279 @default.
• W2800354105 hasConcept C185592680 @default.
• W2800354105 hasConcept C189178095 @default.
• W2800354105 hasConcept C204787440 @default.
• W2800354105 hasConcept C2776164576 @default.
• W2800354105 hasConcept C2776467144 @default.
• W2800354105 hasConcept C2778266237 @default.
• W2800354105 hasConcept C2779689624 @default.
• W2800354105 hasConcept C2780664492 @default.
• W2800354105 hasConcept C55493867 @default.
• W2800354105 hasConcept C61511704 @default.
• W2800354105 hasConcept C71924100 @default.
• W2800354105 hasConcept C98274493 @default.
• W2800354105 hasConceptScore W2800354105C120665830 @default.
• W2800354105 hasConceptScore W2800354105C121332964 @default.
• W2800354105 hasConceptScore W2800354105C126322002 @default.
• W2800354105 hasConceptScore W2800354105C142724271 @default.
• W2800354105 hasConceptScore W2800354105C181199279 @default.
• W2800354105 hasConceptScore W2800354105C185592680 @default.
• W2800354105 hasConceptScore W2800354105C189178095 @default.
• W2800354105 hasConceptScore W2800354105C204787440 @default.
• W2800354105 hasConceptScore W2800354105C2776164576 @default.
• W2800354105 hasConceptScore W2800354105C2776467144 @default.
• W2800354105 hasConceptScore W2800354105C2778266237 @default.
• W2800354105 hasConceptScore W2800354105C2779689624 @default.
• W2800354105 hasConceptScore W2800354105C2780664492 @default.
• W2800354105 hasConceptScore W2800354105C55493867 @default.
• W2800354105 hasConceptScore W2800354105C61511704 @default.
• W2800354105 hasConceptScore W2800354105C71924100 @default.
• W2800354105 hasConceptScore W2800354105C98274493 @default.
• W2800354105 hasLocation W28003541051 @default.
• W2800354105 hasOpenAccess W2800354105 @default.
• W2800354105 hasPrimaryLocation W28003541051 @default.
• W2800354105 hasRelatedWork W1495877526 @default.
• W2800354105 hasRelatedWork W1968117112 @default.
• W2800354105 hasRelatedWork W2021120688 @default.
• W2800354105 hasRelatedWork W2022708774 @default.
• W2800354105 hasRelatedWork W2025161798 @default.
• W2800354105 hasRelatedWork W2025945817 @default.
• W2800354105 hasRelatedWork W2053833211 @default.
• W2800354105 hasRelatedWork W2247731899 @default.
• W2800354105 hasRelatedWork W2953958286 @default.
• W2800354105 hasRelatedWork W3014759756 @default.
• W2800354105 hasVolume "26" @default.
• W2800354105 isParatext "false" @default.
• W2800354105 isRetracted "false" @default.
• W2800354105 magId "2800354105" @default.
• W2800354105 workType "article" @default.